A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

Table 3 Number of patients who had rescue therapy due to GCA by visit—ITT population

n (%)	SAR200 + 26W taper	SAR150 + 26W taper	PBO + 52W taper	PBO + 26W taper
Baseline, n	27	14	28	14
Week 24^a	21	14	24	11
Had rescue therapy	7 (33)	5 (36)	5 (21)	6 (54)
Due to active GCA	7 (33)	5 (36)	4 (17)	4 (36)
Due to elevated ESR attributable to active GCA	0	0	1 (4)	2 (18)
Week 52^a	12	7	14	7
Had rescue therapy	5 (42)	4 (57)	6 (43)	4 (57)
Due to active GCA	5 (42)	4 (57)	5 (36)	2 (29)
Due to elevated ESR attributable to active GCA	0	0	1 (7)	2 (29)

The number of rescue patients was calculated based on the start date and end date of rescue medication
ESR Erythrocyte sedimentation rate, GCA Giant cell arteritis, ITT Intent-to-treat, n Number of patients, PBO Placebo, SAR150/200 Sarilumab 150/200 mg, W Week
^aIncludes patients who were in the study treatment

ISSN: 1478-6362